70 related articles for article (PubMed ID: 22042448)
1. [Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of platinum-based chemotherapy (CRAD001)].
Rexer H
Urologe A; 2011 Nov; 50(11):1464-5. PubMed ID: 22042448
[No Abstract] [Full Text] [Related]
2. [Second line AUO study AB35/09 of metastasized urothelial cell carcinoma].
Rexer H
Urologe A; 2010 Sep; 49(9):1194-5. PubMed ID: 20809295
[No Abstract] [Full Text] [Related]
3. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
[TBL] [Abstract][Full Text] [Related]
4. [First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)].
Rexer H
Urologe A; 2011 Dec; 50(12):1617-8. PubMed ID: 22159705
[No Abstract] [Full Text] [Related]
5. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Vaughn DJ; Manola J; Dreicer R; See W; Levitt R; Wilding G
Cancer; 2002 Sep; 95(5):1022-7. PubMed ID: 12209686
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
7. Review and outlook for the role of paclitaxel in urothelial carcinoma.
Vaughn DJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
[TBL] [Abstract][Full Text] [Related]
8. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Colaço B; Lopes C; Colaço A; Costa C; da Silva VM; Oliveira P; Santos L
Biomed Pharmacother; 2013 Mar; 67(2):116-21. PubMed ID: 23433853
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment to paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
El-Gamal OM
Int J Urol; 2011 May; 18(5):357. PubMed ID: 21453399
[No Abstract] [Full Text] [Related]
10. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
[TBL] [Abstract][Full Text] [Related]
11. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies.
Tu SM; Hossan E; Amato R; Kilbourn R; Logothetis CJ
J Urol; 1995 Nov; 154(5):1719-22. PubMed ID: 7563331
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel in the treatment of advanced urothelial cancer.
Bajorin DF
Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149
[TBL] [Abstract][Full Text] [Related]
17. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
18. Current treatment of metastatic bladder cancer and future directions.
Lei AQ; Cheng L; Pan CX
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
[TBL] [Abstract][Full Text] [Related]
19. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
[TBL] [Abstract][Full Text] [Related]
20. Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
von der Maase H
Eur Urol; 2007 Oct; 52(4):1122. PubMed ID: 17433856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
